Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2
Latest Information Update: 25 Aug 2022
At a glance
- Drugs Esketamine (Primary)
- Indications Tinnitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TACTT2
- Sponsors Altamira Therapeutics; Auris Medical
- 13 Mar 2018 According to an Auris Medical media release, the Company is investigating the outcomes and will provide an update in due course.
- 26 Feb 2018 According to Auris Medical media release, Elias Michaelides, MD (Yale School of Medicine) participated as the principal investigator for this trial.
- 01 Sep 2017 Results assessing safety and tolerability of repeated intratympanic administration of the gel-formulated NMDA receptor antagonist AM-101 in acute patients with inner ear tinnitus, were published in the Otolaryngology - Head and Neck Surgery.